First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab : final analysis of the randomized, phase III iLLUMINATE trial
-
Moreno, Carol (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya))
;
Greil, Richard (Salzburg Cancer Research Institute-CCCIT (Àustria)) ;
Demirkan, Fatih (Dokuz Eylul University (Turquía)) ;
Tedeschi, Alessandra (Niguarda Ca Granda Hospital (Itàlia)) ;
Anz, Bertrand (Tennessee Oncology (Estats Units)) ;
Larratt, Loree (University of Alberta Hospital (Canadà)) ;
Simkovic, Martin (University Hospital and Medical School Hradec (Txèquia)) ;
Novak, Jan (Charles University (Txèquia)) ;
Strugov, Vladimir (Almazov National Medical Research Centre (Rússia)) ;
Gill, Devinder (Princess Alexandra Hospital) ;
Gribben, John G. (Barts Cancer Institute) ;
Kwei, Kevin (Pharmacyclics LLC) ;
Dai, Sandra (Pharmacyclics LLC) ;
Hsu, Emily (Pharmacyclics LLC) ;
Dean, James P. (Pharmacyclics LLC) ;
Flinn, Ian W. (Sarah Cannon Research Institute) ;
Universitat Autònoma de Barcelona